Anti-VEGFR2 (Ramucirumab), Human IgG1 Antibody

Anti-VEGFR2 (Ramucirumab), Human IgG1 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a fully human IgG1 monoclonal antibody that binds to the vascular endothelial growth factor receptor 2 (VEGFR2) and inhibits association with its ligands (VEGF A, C, and D). This prevents VEGF-mediated proliferation, migration of endothelial cells, and angiogenesis. The original monoclonal antibody received FDA approval to treat advanced gastric cancer/gastro-esophageal junction (GEJ) adenocarcinoma. It is also approved for use for the combination treatment of metastatic non-small lung carcinoma (NSLC), metastatic colorectal cancer (mCRC), and hepatocellular carcinoma (HCC).

Immunogen Sequence:Ramucirumab

Target Alternative Name:FLK1, CD309, VEGFR, VEGFR2, KDR

Species Reactivities:Human

Tag Line:A fully human monoclonal antibody that inhibits the association of VEGFR2 with its ligands and prevents VEGF-mediated tumor angiogenesis

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:In vitro studies

Positive Control:/

Application And Usages:In vitro studies

Handling:The antibody solution should be gently mixed before use.